Tracy Cunningham
Director Técnico/Científico/I+D en AMRYT PHARMA PLC .
Cargos activos de Tracy Cunningham
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| AMRYT PHARMA PLC | Director Técnico/Científico/I+D | 01/04/2020 | - |
| Health Research Board | Director/Miembro de la Junta | - | - |
Historial de carrera de Tracy Cunningham
Antiguos cargos conocidos de Tracy Cunningham.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | - | - |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Director Técnico/Científico/I+D | 27/06/2022 | - |
| Corporate Officer/Principal | 01/04/2020 | 27/06/2022 |
Formación de Tracy Cunningham.
| Royal College of Surgeons | Undergraduate Degree |
Estadísticas
Internacional
| Reino Unido | 4 |
| Irlanda | 3 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 2 |
| Government | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Empresas privadas | 3 |
|---|---|
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
| Health Research Board | Government |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland. | Health Technology |
- Bolsa de valores
- Insiders
- Tracy Cunningham
- Experiencia
